Base de dados : LILACS
Pesquisa : D23.101.140 [Categoria DeCS]
Referências encontradas : 1181 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 119 ir para página                         

  1 / 1181 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1048791
Autor: Valdivia P, Carolina; Olivari U, Daniela; Pérez E, María Javiera; Tapia Castillo, Alejandra; Ortiz C, David; Barros L, Eric; Fardella B, Carlos E; Carvajal M, Cristián A; Domínguez R-T, José Miguel.
Título: Estudio de frecuencia y asociación de los polimorfismos RS965513 y RS1867277 del gen FOXE1 con el carcinoma papilar de tiroides y su riesgo de recurrencia en población chilena / Frequency and association of the polymorphisms RS965513 and RS1867277 of the FOXE1 gene with papillary thyroid carcinoma and its risk of recurrence in Chilean population
Fonte: Rev. chil. endocrinol. diabetes;13(1):6-10, 2020. ilus, tab.
Idioma: es.
Projeto: SOCHED; . CONICYT-FONDECYT; . CETREN-UC.
Resumo: Introducción: El gen FOXE1 (Forkhead box E1) codifica para un factor de transcripción involucrado en la morfogénesis tiroidea. El cáncer papilar de tiroides (CPT) se ha asociado con polimorfismos (SNP) de FOXE1 rs1867277 y rs965513 en población asiática y europea. Nuestro objetivo fue investigar la frecuencia y asociación de SNP rs1867277 y rs965513 con CPT y el riesgo de recurrencia de CPT en sujetos chilenos. Métodos: Se reclutaron sujetos con y sin CPT, se describieron sus características epidemiológicas y la forma de presentación clínica (AJCC VIII y MINSAL 2013). Se aisló ADN de leucocitos periféricos y evaluó ambos SNP mediante PCR-HRM y secuencia. Se compararon las frecuencias alélicas y genotípicas entre casos CPT y controles, y entre pacientes CPT de distintos riesgos de recurrencia. Se compararon frecuencia y se estimó el riesgo con test de Fisher y cálculo de odds-ratio (OR). Resultados: De los 184 sujetos, 156 (85%) eran mujeres, edad 39,3±12,3 años; 90 con CPT y 94 sin CPT 26 (28,9%) pacientes eran de riesgo muy bajo, 45 (50%) bajo, 16 (17,8%) intermedio y 3 (3,3%) alto según MINSAL 2013. En relación a la frecuencia de alelo menor (MAF) calculada en sujetos control y CPT, fue 31,7% y 24,5% (SNP rs965513), y 36,7% y 30,1% 8 (rs1867277), respectivamente (p NS). Tampoco fueron diferentes las MAF calculados y comparados entre pacientes con CPT de riesgo bajo e intermedio/alto. Sin embargo, la combinación de los genotipos rs1867277GG y rs965513AA se asoció a mayor riesgo de CPT. Conclusiones: En pacientes chilenos, se describe una frecuencia MAF de los SNP rs1867277 y rs965513 cercana a un 30%, las cuales no se asocian a CPT ni riesgo de recurrencia, sin embargo, sujetos con una combinación genotípica particular podrían tener mayor riesgo de CPT.

FOXE1 gene (Forkhead E1 box) codes for a transcription factor involved in thyroid morphogenesis. Papillary thyroid cancer (PTC) has been associated with FOXE1 polymorphisms (SNPs) rs1867277 and rs965513 in Asian and European population. Our aim was to investigate the frequency and the association of SNPs rs1867277 and rs965513 with PTC and the risk of recurrence of PTC in Chilean subjects. Methods: We recruited subjects with and without PTC. In those with PTC, their epidemiological characteristics and clinical features presentation are described according to AJCC VIII and MINSAL 2013 scales. Peripheral leukocyte DNA was isolated and both SNPs were evaluated using PCR-HRM and sequencing. Allelic and genotypic frequencies were compared between PTC cases and controls, and between PTC patients with different recurrence risks. Results: Of the 184 subjects, 156 (85%) were women, age 39.3 ± 12.3 years; 94 (51%) without PTC and 90 with PTC (49%): 26 (28.9%) patients had very low, 45 (50%) low, 16 (17.8%) intermediate and 3 (3.3%) high risk of recurence according to MINSAL 2013. Regarding the minor allele frequency (MAF) calculated on control and PTC subjects, was 31.7% and 24.5% (SNP rs965513), and 36.7% and 30.1% (rs1867277), respectively (p NS). In patients with PTC, MAFs were not different between patients with low and intermediate/high risk PTC. However, the combination of rs1867277GG and rs965513AA genotypes were associated with an increased risk of PTC. Conclusions: In Chilean patients, the MAF frequency of SNPs rs1867277 and rs965513 is near 30%, and they are are not associated with PTC or its risk of recurrence. However, subjects with a particular genotypic combination may have an increased risk of PTC.
Descritores: Neoplasias da Glândula Tireoide/epidemiologia
Polimorfismo de Nucleotídeo Único
Câncer Papilífero da Tireoide/epidemiologia
-Polimorfismo Genético
Neoplasias da Glândula Tireoide/genética
Biomarcadores Tumorais/genética
Chile/epidemiologia
Reação em Cadeia da Polimerase
Medição de Risco
Predisposição Genética para Doença
Fatores de Transcrição Forkhead/genética
Câncer Papilífero da Tireoide/genética
Frequência do Gene
Genótipo
Recidiva Local de Neoplasia/epidemiologia
Limites: Humanos
Masculino
Feminino
Adulto
Responsável: CL1.1 - Biblioteca Central


  2 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1142586
Autor: Ding, Tianling; Li, Jialing; Sun, Jianhong; Fan, Xiaoman; Shi, Chunli; Zhou, Dong; Deng, Ruoyu.
Título: Association of kinesin family member 2A with increased disease risk, deteriorative clinical characteristics, and shorter survival profiles in acute myeloid leukemia
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(2):e9173, 2021. tab, graf.
Idioma: en.
Projeto: Research Foundation of Shanghai Municipal Commission of Health and Family Planning.
Resumo: This study aimed to explore the correlation of kinesin family member 2A (KIF2A) expression with disease risk, clinical characteristics, and prognosis of acute myeloid leukemia (AML), and investigate the effect of KIF2A knockdown on AML cell activities in vitro. Bone marrow samples were collected from 176 AML patients and 40 healthy donors, and KIF2A expression was measured by real-time quantitative polymerase chain reaction. Treatment response, event-free survival (EFS), and overall survival (OS) were assessed in AML patients. In vitro, KIF2A expression in AML cell lines and CD34+ cells (from healthy donors) was measured, and the effect of KIF2A knockdown on AML cell proliferation and apoptosis in HL-60 and KG-1 cells was detected. KIF2A expression was greater in AML patients compared to healthy donors, and receiver operating characteristic curve indicated that KIF2A expression predicted increased AML risk (area under curve: 0.793 (95%CI: 0.724-0.826)). In AML patients, KIF2A expression positively correlated with white blood cells, monosomal karyotype, and high risk stratification. Furthermore, no correlation of KIF2A expression with complete remission or hematopoietic stem cell transplantation was found. Kaplan-Meier curves showed that KIF2A expression was negatively correlated with EFS and OS. In vitro experiments showed that KIF2A was overexpressed in AML cell lines (KG-1, HL-60, ME-1, and HT-93) compared to CD34+ cells, moreover, cell proliferation was reduced but apoptosis was increased by KIF2A knockdown in HL-60 and KG-1 cells. In conclusion, KIF2A showed potential to be a biomarker and treatment target in AML.
Descritores: Leucemia Mieloide Aguda/diagnóstico
Leucemia Mieloide Aguda/genética
Cinesina/genética
-Biomarcadores Tumorais/genética
Taxa de Sobrevida
Fatores de Risco
Apoptose
Células HL-60
Proliferação de Células
Técnicas de Silenciamento de Genes
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  3 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1153512
Autor: Sun, Lei; Zhou, Xin; Jiang, Qian; Zhuang, Yiping; Li, Dongzheng.
Título: Low miR-1273a expression predicts poor prognosis of colon cancer and facilitates tumor cell proliferation, migration, and invasion
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(2):e10394, 2021. tab, graf.
Idioma: en.
Resumo: MicroRNAs (miRNAs) have been indicated to be frequently dysregulated in various cancers and promising biomarkers for colon cancer. The present study aimed to assess the prognostic significance and biological function of miR-1273a in colon cancer. The expression levels of miR-1273a was estimated using quantitative real-time polymerase chain reaction. Kaplan-Meier survival curves and Cox regression analysis were used to evaluate the prognostic value of miR-1273a in patients of colon cancer. The effects of miR-1273a on cell proliferation, migration, and invasion were investigated by cell experiments. The expression of miR-1273a was downregulated in colon cancer tissues and tumor cell lines compared with the normal controls (all P<0.001). The aberrant expression of miR-1273a was associated with vascular invasion (P=0.005), differentiation (P=0.023), lymph node metastasis (P=0.021), and TNM stage (P=0.004). The patients with low miR-1273a expression had low overall survival compared with the patients with high miR-1273a expression (log-rank P=0.002). miR-1273a was detected to be an independent prognostic biomarker for patients. Furthermore, the results of cell experiments revealed that miR-1273a downregulation promoted, while miR-1273a upregulation suppressed the cell proliferation, migration, and invasion. In conclusion, all data indicated that a downregulated expression of miR-1273a predicted poor prognosis for colon cancer and enhanced tumor cell proliferation, migration, and invasion. Thus, we suggest that methods to promote miR-1273a expression may serve as novel therapeutic strategies in colon cancer.
Descritores: Neoplasias do Colo/diagnóstico
MicroRNAs/genética
-Biomarcadores Tumorais/genética
Movimento Celular/genética
Neoplasias do Colo/genética
Proliferação de Células/genética
Invasividade Neoplásica
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  4 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1249319
Autor: Delmonico, L; Obenauer, J C; Stockfisch, T P; Fournier, M V.
Título: Housekeeping genes involved in non-malignant breast phenotypes are widely expressed in multiple cancers and provide novel biomarkers of tumor classification
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;54(7):e10388, 2021. tab.
Idioma: en.
Projeto: CAPES.
Resumo: Clinically relevant biomarkers are useful to determine cancer patients' prognosis and treatments. To discover new putative biomarkers, we performed in silico analysis of a 325-gene panel previously associated with breast epithelial cell biology and clinical outcomes. Sixteen public datasets of microarray samples representing 8 cancer types and a total of 3,663 patients' samples were used for the analyses. Feature selection was used to identify the best subsets of the 325 genes for each classification, and linear discriminant analysis was used to quantify the accuracy of the classifications. A subset of 102 of the 325 genes were found to be housekeeping (HK) genes, and the classifications were repeated using only the 102 HK subset. The 325-gene panel and 102 HK subset were able to distinguish colon, gastric, lung, ovarian, pancreatic, and prostate tumors and leukemia from normal adjacent tissue, and classify disease subtypes of breast and lung cancers and leukemia with 70% or higher accuracy. HK genes have been overlooked as potential biomarkers due to their relative stability. This study describes a set of HK genes as putative biomarkers applicable to multiple cancer types worth following in subsequent validation studies.
Descritores: Neoplasias da Mama/genética
Perfilação da Expressão Gênica
-Fenótipo
Biomarcadores Tumorais/genética
Regulação Neoplásica da Expressão Gênica
Análise de Sequência com Séries de Oligonucleotídeos
Genes Essenciais
Limites: Humanos
Masculino
Responsável: BR1.1 - BIREME


  5 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-776330
Autor: Gil Parada, Fabio Leonel; Torres Amaya, Marcela; Riveros Santoya, Sandra Viviana; Castaño Llano, Rodrigo; Ibáñez, Heinz; Huertas Quintero, Margarita María; Carmona, Rafael; Pardo, Rodrigo; Otero, William; Sabbagh, Luis.
Título: Guía de práctica clínica para la tamización del cáncer colorrectal - 2015 / Clinical Practice Guideline for the screening of colorectal cancer-2015
Fonte: Rev. colomb. gastroenterol;30(supl.1):67-74, oct.-dic. 2015. ilus.
Idioma: es.
Resumo: Objetivo: desarrollar una guía de práctica clínica con la evidencia más reciente para la tamización de cáncer de colon y recto en población asintomática de riesgo promedio, dirigida a pacientes, personal asistencial, administrativo y entes gubernamentales de cualquier servicio de atención en Colombia. Materiales y métodos: esta guía fue desarrollada por un equipo multidisciplinario con apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad; ninguna de ellas cumplió el criterio de adaptación, por lo que se decidió construir una guía de novo. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas con base en la metodología GRADE. Las recomendaciones de la guía fueron socializadas en una reunión de expertos con entes gubernamentales y pacientes. Resultados: se desarrolló una guía de práctica clínica basada en la evidencia para la tamización del cáncer de colon y recto en Colombia. Conclusiones: la tamización de pacientes asintomáticos de riesgo promedio en Colombia en forma adecuada con estándares de calidad tiene el potencial de impactar la carga de cáncer de colon en el país.

Objective: To provide an evidence-based clinical practice guideline for the screening of colon and rectal cancer for patients, caregivers, administrative and government bodies at all levels of care in Colombia. Materials and Methods: This guide was developed by a multidisciplinary team with the support of the Colombian Association of Gastroenterology, Cochrane STI Group and Clinical Research Institute of the Universidad Nacional de Colombia. Relevant clinical questions were developed and the search for national and international guidelines in databases was performed. Existing guidelines were evaluated for quality and applicability. None of the guidelines met the criteria for adaptation, so the group decided to develop a de novo guideline. Systematic literature searches were conducted by the Cochrane Group. The tables of evidence and recommendations were made based on the GRADE methodology. The recommendations of the guide were socialized in a meeting of experts with government agencies and patients. Results: An evidence-based Clinical Practice Guidelines for the screening of colorectal cancer was developed for the Colombian context. Conclusions: The opportune detection of colon cancer would have an impact of the disease in Colombia.
Descritores: Neoplasias Colorretais/diagnóstico
Programas de Rastreamento
-Biomarcadores Tumorais
Fatores de Risco
Sensibilidade e Especificidade
Colonoscopia
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Guia de Prática Clínica
Responsável: BR1.1 - BIREME


  6 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-952054
Autor: Silva, Fernanda Paula Yamamoto; Dias, Andrielle; Coelho, Carolinne Almeida; Guerra, Eliete Neves; Marques, Ana Elizia Mascarenhas; Decurcio, Daniel de Almeida; Mantesso, Andrea; Cury, Sérgio Elias Vieira; Silva, Brunno Santos de Freitas.
Título: Expression of CD90 and P75NTR stem cell markers in ameloblastomas: a possible role in their biological behavior
Fonte: Braz. oral res. (Online);30(1):e109, 2016. tab, graf.
Idioma: en.
Resumo: Abstract Multicystic and unicystic ameloblastomas are benign odontogenic tumors that present distinct biological behavior. The investigation of stem cells has become an important branch of tumor biology, with several studies addressing the possible role of these cells in tumor growth, angiogenesis, progression, infiltration and invasiveness. This study evaluated the immunohistochemical expression of CD90(Thy-1) and P75NTR stem cell markers in multicystic and unicystic ameloblastomas. Seventeen (17) samples of ameloblastomas (multicystic, n = 10; unicystic, n = 7) were submitted to immunohistochemical reactions and graded semi-quantitatively. The Kolmogorov-Smirnov test was used to verify possible differences in CD90 and P75NTR expressions between multicystic and unicystic ameloblastomas (p < 0.05). CD90 immunostaining was observed in all multicystic ameloblastoma specimens (n = 10), in the cytoplasm of the fibroblasts and vascular endothelial cells of the tumor stroma, near the neoplastic odontogenic epithelia. The staining of stromal CD90 was significantly higher in multicystic than in unicystic ameloblastomas (p = 0.003). Nuclear P75NTR immunostaining was observed in all ameloblastoma specimens. A significant difference was seen in the epithelial staining of P75NTR between multicystic and unicystic types (p = 0.007). The increased expression of CD90 and P75NTR found in multicystic ameloblastomas suggests a behavioral biological difference between multicystic and unicystic ameloblastomas, as well as a difference in ameloblastoma development.
Descritores: Células-Tronco Neoplásicas/metabolismo
Ameloblastoma/metabolismo
Neoplasias Mandibulares/metabolismo
Biomarcadores Tumorais/metabolismo
Receptores de Fator de Crescimento Neural/metabolismo
Antígenos Thy-1/metabolismo
Proteínas do Tecido Nervoso/metabolismo
-Células-Tronco Neoplásicas/patologia
Imuno-Histoquímica
Ameloblastoma/patologia
Neoplasias Mandibulares/patologia
Inclusão em Parafina
Células Estromais
Estatísticas não Paramétricas
Células Endoteliais/metabolismo
Fibroblastos/metabolismo
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  7 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Souza, Lélia Batista de
Texto completo
Id: biblio-952146
Autor: Serpa, Marianna Sampaio; Mafra, Rodrigo Porpino; Queiroz, Salomão Israel Monteiro Lourenço; Silva, Leorik Pereira da; Souza, Lélia Batista de; Pinto, Leão Pereira.
Título: Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue
Fonte: Braz. oral res. (Online);32:e93, 2018. tab, graf.
Idioma: en.
Resumo: Abstract Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) act in the proteolysis of basement membrane and extracellular matrix structures, facilitating tumor invasion. The purpose of this study was to evaluate the relationship between these proteins and clinicopathological parameters in squamous cell carcinoma of the oral tongue (SCCOT). Sixty cases of SCCOT were submitted to immunohistochemistry and analyzed semiquantitatively at the invasion front and in the tumor core. The results were associated with lymph node metastasis, clinical stage, locoregional recurrence, clinical outcome and histological grade of malignancy. A higher expression of uPA was observed in cases of tumors of high-grade versus low-grade malignancy (p = 0.010). Moreover, the cases with the worst pattern of invasion presented an overexpression of uPA (p = 0.011). The presence of locoregional recurrence was associated with uPAR (p = 0.039), and the expression of both biomarkers was much higher at the invasion front than in the tumor core (p < 0.001). The results suggest uPA and uPAR are involved in the progression and aggressiveness of SCCOT, mainly at the tumor-host interface.
Descritores: Neoplasias da Língua/química
Carcinoma de Células Escamosas/química
Ativador de Plasminogênio Tipo Uroquinase/análise
Receptores de Ativador de Plasminogênio Tipo Uroquinase/análise
-Valores de Referência
Neoplasias da Língua/patologia
Imuno-Histoquímica
Carcinoma de Células Escamosas/patologia
Biomarcadores Tumorais/análise
Fatores de Risco
Estatísticas não Paramétricas
Gradação de Tumores
Pessoa de Meia-Idade
Invasividade Neoplásica
Recidiva Local de Neoplasia/patologia
Recidiva Local de Neoplasia/química
Estadiamento de Neoplasias
Limites: Humanos
Masculino
Feminino
Responsável: BR1.1 - BIREME


  8 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Ramalho, Luciana Maria Pedreira
Texto completo
Texto completo
Id: biblio-1247694
Autor: Silva, Lorena Ferraz Santos; Ramalho, Luciana Maria Pedreira.
Título: Análise comparativa entre a coloração do azul de toluidina e a imunoexpressão da ciclina D1 em leucoplasias da mucosa bucal com diferentes graus de atipia / Comparative analysis between the coloring of toluidine blue and the immunoexpression of cyclin D1 in leucoplakias of the bucal mucosa with different degrees of atipia
Fonte: Rev. Ciênc. Méd. Biol. (Impr.) = J. med. biol. sci;17(3):322-329, nov 19, 2018. tab, ilus.
Idioma: pt.
Resumo: O câncer de boca ocupa uma posição de destaque em relação ao número total de casos registrados no Brasil. A displasia epitelial (DE) oral é um achado histopatológico associado a um risco aumentado de transformação maligna do epitélio oral. A falha nos mecanismos de sinalização celular, no controle do ciclo celular ou nos mecanismos para reparar danos celulares pode favorecer a processos que culminam com a progressão para o câncer. Objetivo: avaliar comparativamente a resposta clínica da marcação do azul de toluidina (AT) e a imunoexpressão da proteína ciclina D1, uma proteína nuclear de grande importância como regulador da transição da fase G1 para fase S do ciclo celular, em leucoplasias oral (LO). Metodologia: avaliamos 12 pacientes que apresentavam, na cavidade bucal, lesões com diagnóstico clínico de LO. O estudo se desenvolveu em duas etapas: clínica e laboratorial. Foi feita marcação com AT e avaliação Imuno-histoquímica, respectivamente. Após análise quantitativa das lâminas, os dados obtidos foram analisados pelo programa BIOESTAT 2.0, por meio dos testes de Spearman e pelo teste de correlações múltiplas de Pearson. Resultados: não foi observada relação entre a marcação clínica do AT, o grau de displasia da lesão e a imunoexpressão da Ciclina D1 em LO. Conclusão: 82% das lesões apresentaram DE em graus variados, confirmando a necessidade de se realizar o diagnóstico histopatológico das LO e o acompanhamento clínico posterior dos pacientes.

Mouth cancer occupies a prominent position in relation to the total number of cases registered in Brazil. Oral epithelial dysplasia (ED) is a histopathological finding associated with an increased risk of malignant transformation of oral epithelium. The failure in the mechanisms of cell signaling, cell cycle control mechanisms or to repair cell damage can favor processes that culminate with the progression to cancer. Objective: evaluate comparatively the clinical response of the toluidine blue marking (TB) and immuno-expression of cyclin D1 protein, a nuclear protein of great importance as a factor regulating the transition from G1 phase to S phase of the cell cycle, in oral leukoplakia (OL). Methodology: we evaluated 12 patients who presented lesions in the oral cavity with clinical diagnosis of OL. The study was developed in two stages: Clinical and Laboratorial. Marking was made with TB and immunohistochemical evaluation, respectively. After quantitative analysis of blades, the data obtained were analyzed by BIOESTAT program 2.0 through Spearman tests and by Pearson multiple correlation test. Results: no relation was observed between clinical marking of TB, the degree of dysplasia of the lesion and the immuno-expression of Cyclin D1 in OL. Conclusion: 82% of the lesions presented DE in varying degrees, confirming the need to perform histopathological diagnosis of the OL and the subsequent clinical monitoring of the patients.
Descritores: Cloreto de Tolônio
Leucoplasia Oral/patologia
Biomarcadores Tumorais/análise
Ciclina D1/análise
Corantes
-Imuno-Histoquímica
Progressão da Doença
Limites: Humanos
Tipo de Publ: Estudo Comparativo
Responsável: BR342.1 - Biblioteca Universitária de Saúde


  9 / 1181 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974437
Autor: Lao, Thuan Duc; Nguyen, Truong Van; Nguyen, Dung Huu; Nguyen, Minh Trong; Nguyen, Chuong Hoang; Le, Thuy Huyen Ai.
Título: miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma
Fonte: Braz. oral res. (Online);32:e126, 2018. graf.
Idioma: en.
Resumo: Abstract: Novel biomarkers for screening, diagnosis and monitoring the treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in Vietnam, are urgently required. Increasing evidence suggests that microRNA-141 (miR-141) is associated with NPC, owing to its ability to affect the expression of genes that modulate tumorigenesis. Unfortunately, research on miR-141 expression in Vietnamese patients is limited. Therefore, the objective of the current study was to evaluate miR-141 expression and assess whether miR-141 might be a potential biomarker for diagnosis of NPC in Vietnamese patients. Total RNA isolated from 40 NPC biopsy samples and 37 non-cancerous samples was analyzed by quantitative reverse-transcription PCR. The miR-141 expression levels were compared between NPC biopsy and non-cancerous samples. The frequency of miR-141 detection was 37.50% and 10.80% in the NPC and non-cancerous samples, respectively (p = 0.0143). The miR-141 expression was 5.27 times higher in tumor samples than non-cancerous samples. Additionally, the RR (Relative risk) and OR (Odds ratio) were 1.83 (95%CI = 1.2576-2.6675, p = 0.0016) and 4.95 (95%CI = 1.4625-16.7541, p = 0.01), respectively. In conclusion, miR-141 was up-regulated in the biopsy samples and thus may be a potential biomarker for NPC in the Vietnamese population.
Descritores: Neoplasias Nasofaríngeas/genética
MicroRNAs/análise
Carcinoma Nasofaríngeo/genética
-Valores de Referência
Vietnã
Biomarcadores Tumorais/análise
Estudos de Casos e Controles
Regulação para Cima
Neoplasias Nasofaríngeas/patologia
Grupo com Ancestrais do Continente Asiático
Reação em Cadeia da Polimerase em Tempo Real
Carcinoma Nasofaríngeo/patologia
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  10 / 1181 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1045739
Autor: Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaLi, M; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaGuo, S-J; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaShen, Y-C; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaJia, L-Q; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaLi, D-D; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaWan, C; Department of Respiratory Medicine. State Key Laboratory of Biotherapy of ChinaWen, F-Q.
Título: Diagnostic value of p16 methylation for malignant pleural effusion a meta-analysis / Valor diagnóstico de la metilación p16 en el derrame pleural maligno un meta-análisis
Fonte: West Indian med. j;62(8):716-720, Nov. 2013. ilus, tab.
Idioma: en.
Projeto: National Natural Science Foundation of China; . China Medical Board of New York.
Resumo: OBJECTIVE: To evaluate the overall diagnostic performance of the p16 methylation for diagnosing malignant pleural effusion (MPE). METHODS: All published literature in English and Chinese were reviewed. Sensitivity, specificity, likelihood ratio and diagnostic odds ratio (DOR) were pooled by using random-effects model or fixed-effects model. Summary receiver operating characteristic (SROC) curve was used to evaluate the overall diagnostic value. RESULTS: Six studies were included with a total of 378 cases. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and DOR of p16 methylation in the diagnosis of MPE were 0.41 [95% confidence interval (CI) 0.35, 0.48], 0.97 [95% CI 0.93, 0.99], 9.57 [95% CI 4.53, 20.20], 0.61 [95% CI 0.45, 0.82] and 19.82 [95% CI 8.35, 47.04], respectively. The area under the curve (AUC) was 0.864. CONCLUSION: Pleural p16 methylation test plays a useful role in the diagnosis of MPE.

OBJETIVO: Evaluar el rendimiento diagnóstico general de la metilación p16 para el diagnóstico del derrame pleural maligno (DPM). MÉTODOS: Se revisó toda la literatura publicada en inglés y chino. La sensibilidad, especificidad, razón de verosimilitud, y el odds-ratio diagnóstico (DOR) fueron agrupados mediante el modelo de efectos aleatorios o el modelo de efectos. La curva de las características operativas de resumen del receptor (SROC) fue usada para evaluar el valor diagnóstico general. RESULTADOS: Se incluyeron seis estudios con un total de 378 casos. La sensibilidad, especificidad, razón de verosimilitud positiva (PLR), razón de verosimilitud negativa (NLR) y el DOR de la metilación p16 en el diagnóstico de DPM, fueron 0.41 [95% intervalo de confianza (IC) 0.35 0.48], 0.97 [95% IC 0.93, 0.99], 9.57 [95% IC 4.53, 20.20], [95% IC 0.45, 0.82] 0.61 y 19.82 [95% IC 8.35, 47.04], respectivamente. El área bajo la curva (AUC) fue 0.864. CONCLUSIÓN: La prueba de metilación p16 pleural desempeña un papel útil en el diagnóstico del DPM.
Descritores: Derrame Pleural Maligno/diagnóstico
Derrame Pleural Maligno/genética
Genes p16
Metilação
-Biomarcadores Tumorais/genética
Sensibilidade e Especificidade
Limites: Humanos
Tipo de Publ: Revisão Sistemática
Responsável: BR1.1 - BIREME



página 1 de 119 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde